Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Laure Dutrieux, Elle Loughran, Armelle Choquet, Hélène Herault, Antoine Guillemin, Nicolas Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Eric Rivals, Alexandre David, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2023-184749

Published: 2023

Journal Articles

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Elvira Garcia De Paco, Caroline Soulet, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Laure Vincent, Charles Herbaux, Maria Moriel-Carretero, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2023-181039

Published: 2023

Journal Articles

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Elina Alaterre, Nicolas Robert, Guilhem Requirand, Amélie Machura, Hugues De Boussac, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2023-181767

Published: 2023

Journal Articles

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

Alizée Steer, Elina Alaterre, Djamila Chamlal, Emmanuel Varlet, Amélie Machura, Alboukadel Kassambara, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Hugues De Boussac, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2023-180877

Published: 2023

Journal Articles

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Guilhem Requirand, Nicolas Robert, Elina Alaterre, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angélique Bruyer, Hugues De Boussac, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 4220–4221.

https://doi.org/10.1182/blood-2022-163261

Published: 2022

Journal Articles

Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies

Valentin Jacquier, Antoine Guillemin, Sara Ovejero-Merino, Guilhem Requirand, Ouissem Karmous-Gadacha, Laure Dutrieux, Andrea Romero, Alizée Steer, Amelie Machura, Hugues De Boussac, Jerome Moreaux, Charles Herbaux

Blood (2022) 140 (Supplement 1): 10727–10728.

https://doi.org/10.1182/blood-2022-163207

Published: 2022

Journal Articles

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

Sara ovejero-Merino, Julie Devin, Tatiana Cañeque, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizée Steer, Amelie Machura, Christophe Hirtz, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 9980–9981.

https://doi.org/10.1182/blood-2022-163252

Published: 2022

Journal Articles

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Sara ovejero-Merino, Laura Alibert, Julie Devin, Tatiana Cañeque, Ouissem Karmous Gadacha, Matthieu Abouladze, Guilhem Requirand, Nicolas Robert, Hugues De Boussac, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Jerome Moreaux, Caroline Bret

Blood (2022) 140 (Supplement 1): 6439–6440.

https://doi.org/10.1182/blood-2022-164644

Published: 2022

Journal Articles

Genomic Characterization of in Vitro Acquired-Resistance to Proteasome Inhibitors

Hugues De Boussac, Alboukadel Kassambara, Amelie Machura, Djamila Chemlal, Claire Gourzones, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2021) 138 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2021-148584

Published: 2021

Journal Articles

Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

Laure Dutrieux, Yea-Lih Lin, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux

Blood (2021) 138 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2021-151530

Published: 2021

Journal Articles

Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma

Elina Alaterre, PhD, Laurie Herviou, Hugues De Boussac, PhD, Giorgio Papadopoulos, PhD, Stéphanie Boireau, Nicolas Robert, Guilhem Requirand, Angelique Bruyer, Sara Ovejero-Merino, PhD, Laure Vincent, Anne Marie Martinez, Giacomo Cavalli, PhD, Jerome Moreaux, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-138801

Published: 2020

Journal Articles

Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs

Laurie Herviou, Alboukadel Kassambara, PhD, Stephanie Boireau, PhD, Nicolas Robert, Guilhem Requirand, Laure Vincent, MD, Anja Seckinger, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Giacomo Cavalli, PhD, Jerome Moreaux, PhD

Blood (2016) 128 (22): 311.

https://doi.org/10.1182/blood.V128.22.311.311

Published: 2016

Journal Articles

Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?

Anouk Caraux, PhD, Laure Vincent, Jerome Moreaux, PhD, Guilhem Requirand, Caroline Bret, PharmD, PhD, Jean-Luc Veyrune, PhD, Christophe Duperray, Salahedine Bouhya, MD, Jean-Francois Rossi, MD, PhD, Bernard Klein, PhD

Blood (2011) 118 (21): 131.

https://doi.org/10.1182/blood.V118.21.131.131

Published: 2011

Journal Articles

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

Jerome Moreaux, Dirk Hose, Alboukadel Kassambara, Thierry Reme, Philippe Moine, Guilhem Requirand, Hartmut Goldschmidt, Bernard Klein

Blood (2011) 117 (4): 1280–1290.

https://doi.org/10.1182/blood-2010-04-279760

Published: 2011

Includes: Supplemental data

Journal Articles

Osteoclast Gene Expression Profiling in Multiple Myeloma

Jerome Moreaux, Dirk Hose, Thierry Rème, Philippe Moine, Karène Mahtouk, Marion Moos, Guilhem Requirand, John De Vos, PhD, Jean François Rossi, Hartmut Goldschmidt, Bernard Klein

Blood (2008) 112 (11): 2735.

https://doi.org/10.1182/blood.V112.11.2735.2735

Published: 2008

Journal Articles

Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma.

Maud Condomines, PhD, Dirk Hose, PhD, MD, Thierry Reme, PhD, John de Vos, PhD, MD, Guilhem Requirand, Jean-Francois Rossi, PhD, MD, Hartmunt Goldschmidt, PhD, MD, Bernard Klein

Blood (2007) 110 (11): 1793.

https://doi.org/10.1182/blood.V110.11.1793.1793

Published: 2007

Journal Articles

A Phase I/II Study of TACI-Ig To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma or Active Previously-Treated Waldenström’s Macroglobulinemia.

Jean-Francois Rossi, MD, Isabelle Borghini-Fuhrer, PhD, Jerôme Moreaux, Guilhem Requirand, Said Bouseida, Marie Picard, Arnaud Ythier, MD, Eric Sievers, MD, Bernard Klein, PhD

Blood (2005) 106 (11): 2566.

https://doi.org/10.1182/blood.V106.11.2566.2566

Published: 2005

Journal Articles

Syndecan-1 Is Essential for the Myeloma Cell Growth Factor Activity of EGF-Family Ligands in Multiple Myeloma.

Karène Mahtouk, Friedrich W. Cremer, Thierry Rème, Michel Jourdan, Marion Baudard, Jérome Moreaux, Guilhem Requirand, Geneviève Fiol, John De Vos, Marion Moos, Philippe Quittet, Hartmut Goldschmidt, Jean-Francois Rossi, Dirk Hose, Bernard Klein

Blood (2005) 106 (11): 626.

https://doi.org/10.1182/blood.V106.11.626.626

Published: 2005

Journal Articles

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

John De Vos, Guilhem Couderc, Karin Tarte, Michel Jourdan, Guilhem Requirand, Marie-Claude Delteil, Jean-François Rossi, Nadir Mechti, Bernard Klein

Blood (2001) 98 (3): 771–780.

https://doi.org/10.1182/blood.V98.3.771

Published: 2001

NARROW

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Genomic Characterization of in Vitro Acquired-Resistance to Proteasome Inhibitors

Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma

Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs

Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

Osteoclast Gene Expression Profiling in Multiple Myeloma

Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma.

A Phase I/II Study of TACI-Ig To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma or Active Previously-Treated Waldenström’s Macroglobulinemia.

Syndecan-1 Is Essential for the Myeloma Cell Growth Factor Activity of EGF-Family Ligands in Multiple Myeloma.

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only